We are live on
!
Find out more
WCM
Wildcat Capital Management Portfolio holdings
AUM
$229M
1-Year Est. Return
132.65%
This Fund
S&P 500
This Quarter
Est. Return
-5.28%
1 Year Est. Return
+132.65%
3 Year Est. Return
+125.67%
5 Year Est. Return
+54.1%
10 Year Est. Return
+1,929.91%
AUM
$168M
AUM Growth
-$19.1M
(-10%)
Cap. Flow
-$5.12M
Cap. Flow
% of AUM
-3.04%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
–
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$4.05M |
| 2 |
KRON
Kronos Bio
KRON
|
+$1.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 70.36% |
| 2 | Consumer Staples | 23.7% |
| 3 | Healthcare | 5.94% |
Similar funds
AFO
CNHF
GCM
CM
CSIA
AF
NIA
HFA
Wildcat Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Wildcat Capital Management held 8 positions worth $168M, down 10% from $187M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Wildcat Capital Management withdrew a net $5.12M in Q2 2025, closing 2 positions. Its most notable exit was Centessa Pharmaceuticals, an estimated $4.05M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 70% of assets, down from 74% a quarter earlier, followed by Consumer Staples and Healthcare.
- Wildcat Capital Management fully exited Centessa Pharmaceuticals in Q2 2025, selling an estimated $4.05M.
- Wildcat Capital Management's ten largest holdings make up 100% of its $168M portfolio in Q2 2025.
- Wildcat Capital Management opened 0 new positions and closed 2 in Q2 2025.
- Wildcat Capital Management's portfolio value fell 10% quarter-over-quarter to $168M.
Based on Wildcat Capital Management's 13F filing for Q2 2025, filed 18 Jul 2025.